Price
Target price
€1.25
€1.25
2.460%
0.03
2.460%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
China Medical System Holdings Ltd Stock
There is an upward development for China Medical System Holdings Ltd compared to yesterday, with an increase of €0.030 (2.460%).
Pros and Cons of China Medical System Holdings Ltd in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of China Medical System Holdings Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| China Medical System Holdings Ltd | 2.460% | -2.344% | 12.613% | 56.250% | 38.122% | -11.972% | 15.741% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 1.090% | -2.105% | -2.105% | -23.770% | -15.455% | -30.075% | -19.828% |
| Shanghai Fosun Pharmaceutical Group Co Ltd | 1.850% | -7.334% | 9.671% | 11.891% | 2.729% | -52.433% | -41.424% |
| Tianjin Zhon.xin Ph.s Yc1 | 1.310% | 1.979% | 7.102% | -1.435% | 8.065% | 111.991% | 186.623% |
News
3 Health Insurance Stocks Holding Green in Market Turmoil
During the recent market turmoil, three healthcare stocks have performed very well. Those stocks are deeply involved in the health insurance industry. They reacted positively after President
Dr. Oz Officially Confirmed as Head of the Centers for Medicare and Medicaid Services. Here's What Retirees Need to Know So Far.
From TV star to powerful government official. That's the path taken by President Donald Trump and his new administrator of the Centers for Medicare and Medicaid Services (CMS) -- Dr. Mehmet Oz.
Oz
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2